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Abstract
The	specialties	of	allergy	and	clinical	immunology	have	entered	the	era	of	precision	
medicine	with	the	stratification	of	diseases	into	distinct	disease	subsets,	specific	di‐
agnoses,	and	targeted	treatment	options,	including	biologicals	and	small	molecules.	
This	 article	 reviews	 recent	 developments	 in	 research	 and	 patient	 care	 and	 future	
trends	in	the	discipline.	The	section	on	basic	mechanisms	of	allergic	diseases	sum‐
marizes	the	current	status	and	defines	research	needs	in	structural	biology,	type	2	
inflammation,	 immune	 tolerance,	 neuroimmune	 mechanisms,	 role	 of	 the	 microbi‐
ome	and	diet,	environmental	factors,	and	respiratory	viral	infections.	In	the	section	
on	diagnostic	challenges,	clinical	 trials,	precision	medicine	and	 immune	monitoring	
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1  | INTRODUC TION
The	past	decades	have	witnessed	extensive	progress	 in	unraveling	
cellular	and	molecular	mechanisms	of	immune	regulation	in	asthma,	
allergic	diseases,	organ	transplantation,	autoimmune	diseases,	tumor	
biology,	and	chronic	infections.1,2	Consequently,	a	better	understand‐
ing	of	 the	 functions,	 the	reciprocal	 regulation,	and	the	counterbal‐
ance	of	subsets	of	immune	and	inflammatory	cells	but	also	structural	
cells—for	example,	epithelial	and	vascular	cells,	airway	smooth	mus‐
cle	cells,	neuroendocrine	system—that	interact	via	various	intercel‐
lular	messengers	will	indicate	avenues	for	immune	interventions	and	
novel	 treatment	modalities	 of	 allergic	 diseases	 and	 immunological	
disorders.	It	is	generally	expected	that	drug	development	in	the	next	
decades	will	 show	a	 significant	 shift	 from	chemicals	 to	biologicals.	
After	more	 than	20	 years	without	 any	 breakthrough	drug	 becom‐
ing	available	for	patients,	several	disciplines	including	allergology	are	
now	experiencing	extraordinary	 times	with	 the	 recent	 licensing	of	
several	major	biological	drugs	and	novel	allergen‐specific	 immuno‐
therapy	 (AIT)	vaccines.	Several	biological	modifiers	of	 the	 immune	
response	targeting	intracellular	messengers	or	their	receptors	have	
been	developed	to	date.3‐8	In	addition,	a	number	of	promising	small	
molecule	drugs	and	vaccines	are	in	the	development	pipeline.9‐11	This	
new	era	is	now	calling	for	the	development	of	biomarkers	and	pheno‐	
and	 endotyping	 of	 diseases	 for	 customized	 patient	 care,	 which	 is	
termed	 stratified	 medicine,	 precision	 medicine,	 or	 personalized	
medicine.4	Distinguishing	phenotypes	of	 a	 complex	disease	 covers	
the	observable	clinically	relevant	properties	of	the	disease	but	does	
not	show	a	direct	relationship	to	disease	etiology	and	pathophysiol‐
ogy.	In	a	complex	condition,	such	as	asthma,	different	pathogenetic	
mechanisms	can	induce	similar	clinical	manifestations;	however,	they	
may	require	different	treatment	approaches.12,13	These	pathophysi‐
ological	mechanisms	underlying	disease	subgroups	are	addressed	by	
the	term	“endotype.”12‐14	Classification	of	complex	diseases	based	on	
the	concept	of	endotypes	provides	advantages	for	epidemiological,	
genetic,	and	drug‐related	studies.	Accurate	endotyping	by	using	re‐
liable	biomarkers	reflects	the	natural	history	of	the	disease	and	aims	
to	 predict	 the	 response	 to	 (targeted)	 treatments.15	 Recent	 studies	
have	focused	on	better	understanding	of	endotypes	and	phenotypes	
of	allergic	diseases,	asthma,	allergic	and	chronic	rhinosinusitis	±	nasal	
polyps,	chronic	obstructive	pulmonary	disease,	and	on	the	develop‐
ment	of	biomarkers	including	novel	interleukins	and	microRNAs	that	
regulate	their	expression	to	stratify	patients.16‐18
2  | BA SIC MECHANISMS OF ALLERGIC 
DISE A SES—KE Y QUESTIONS
2.1 | Structural and functional biology of allergens—
where are we at?
Cloning	of	allergen	cDNAs	and	sequencing	of	purified	natural	aller‐
gens	have	so	far	yielded	919	officially	accepted	allergenic	proteins	
listed	 in	 the	 database	 of	 the	 WHO/IUIS	 Allergen	 Nomenclature	
Sub‐Committee	 (http://www.aller	gen.org/;	 accessed	 11/2018).	
Structures	 of	 allergens	 determined	 by	 crystallography	 or	 NMR	
amount	to	around	100	as	summarized	in	the	Structural	Database	of	
Allergenic	Proteins	(http://fermi.utmb.edu/;	accessed	11/2018)	and	
by	Dall'Antonia	et	al19	Structural	data	of	allergens	allow	the	study	of	
of	allergic	diseases,	asthma,	allergic	and	nonallergic	rhinitis,	and	new	approaches	to	
the	diagnosis	and	treatment	of	drug	hypersensitivity	reactions	are	discussed	in	fur‐
ther	detail.	In	the	third	section,	unmet	needs	and	future	research	areas	for	the	treat‐
ment	of	allergic	diseases	are	highlighted	with	topics	on	food	allergy,	biologics,	small	
molecules,	 and	 novel	 therapeutic	 concepts	 in	 allergen‐specific	 immunotherapy	 for	
airway	disease.	Unknowns	and	future	research	needs	are	discussed	at	the	end	of	each	
subsection.
K E Y W O R D S
allergy,	exposome,	microbiome,	neuroimmune,	respiratory	viral	infections
How to expand the understanding of allergens and 
allergic sensitization?
•	 Provide	 structures	 of	 homologous	 allergens	 to	 study	
cross‐reactivity
•	 Provide	structures	of	hypoallergenic	variants	to	visual‐
ize	the	effects	of	allergen	design
•	 Provide	structures	for	all	major	allergen	types
•	 Provide	 structures	 for	 allergens	 complexed	 with	 IgE	
Fabs,	IgG	Fabs,	or	single‐chain	antibodies
•	 Provide	structures	of	allergens	with	their	ligands
•	 Perform	studies	on	the	effect	of	the	biological	function	
of	allergens	on	innate	immune	cells
•	 Perform	 studies	 on	 signal	 transduction	 initiated	 by	 al‐
lergens	in	innate	immune	cells
•	 Define	 pattern	 recognition	 receptors,	 membrane	 con‐
stituents,	or	other	cellular	binding	partners	of	allergens
•	 Define	“susceptibility	to	allergic	sensitization”	at	the	mo‐
lecular	and	mechanistic	level
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cross‐reactivities	 between	 related	 allergens,20	 or	 the	design	of	 al‐
lergens	with	 altered	 IgE	 epitopes	 as	 vaccine	 candidates	 for	AIT.21 
The	 location	of	 IgE‐binding	 epitopes	 can	be	determined	based	on	
allergen	 structures	 and	 experimental	 data.22	 Various	 technologies	
exist	for	mapping	conformational	IgE	epitopes.23	X‐ray	crystallogra‐
phy	of	an	allergen‐antibody	complex	allows	the	most	precise	identi‐
fication	of	conformational	epitopes.	To	date,	only	two	structures	of	
cocrystals	of	IgE	and	allergen	are	available,	Bos	d	524	and	Phl	p	2,25 
both	complexed	with	an	IgE	Fab.	Sequence	and	structural	data	have	
revealed	that	allergens	are	members	of	a	limited	number	of	protein	
families	 (http://www.medun	iwien.ac.at/allfa	m/).	 This	 insight	 has	
now	become	mainstream	knowledge	and	indicates	that	the	biologi‐
cal	functions	of	allergens	might	be	linked	to	their	allergenicity.26
Various	 explanations	 for	 the	 existence	 of	 the	 allergic	 immune	
response	have	been	brought	 forward	 including	the	toxin	hypothe‐
sis,27,28	the	danger	theory,29	and	the	allergic	host	defense	model.30 
Unequivocally,	 these	 authors27‐30	 argue	 that	 it	 is	 a	 common	 mis‐
conception	to	regard	allergens	as	generally	harmless	environmental	
substances.	 Allergens	 interact	 with	 innate	 immune	 receptors	 (eg,	
TLR4,31	 protease‐activated	 receptor‐2,32	 dectin‐133),	 disrupt	 the	
integrity	of	membranes	 (eg,	phospholipase	A2,34,35	defensins36,37),	
or	degrade	connective	tissues	(eg,	hyaluronidases38).	However,	very	
few	studies	on	why	only	susceptible	individuals	raise	an	allergic	im‐
mune	response	have	come	forward.	They	indicate	that	genetic	sus‐
ceptibility	 is	based	on	altered	signal	processing39	and	mutations	of	
pattern	recognition	receptors.33
F I G U R E  1  Molecular	mechanisms	in	allergic	inflammation.	Epithelial	leakiness	and	activation	and	their	proinflammatory	cytokine	and	
chemokine	(TNF‐α,	IL‐13,	TSLP,	IL‐25,	IL‐33)	production	induce	inflammation	and	contribute	to	the	Th2	response.	Highly	activated	epithelial	
cells	undergo	apoptosis	and	shedding	takes	place.	Chemokines	are	essential	players	for	the	recruitment	of	inflammatory	cells	followed	
by	survival	and	reactivation	of	migrating	inflammatory	cells	and	their	interaction	with	resident	tissue	cells	and	other	inflammatory	cells.	
Innate	lymphoid	cells	(ILC2)	play	a	role	in	T‐	and	B‐cell	activation	and	recruitment	and	are	early	providers	of	type	2	cytokines	and	T‐cell	
recruitment‐related	chemokines.	The	Th2	type	of	an	immune	microenvironment	is	characterized	by	IL‐4,	IL‐5,	IL‐9,	IL‐13,	IL‐25,	IL‐33	
production	by	Th2	cells,	ILCs,	mast	cells,	and	tissue	cells.	Eosinophilia	is	induced	by	IL‐5,	IL‐25,	and	IL‐33.	Local	and	systemic	IgE	production	
takes	place	in	allergic	patients	with	the	involvement	of	IL‐4	and	IL‐13.	Other	effector	T‐cell	subsets,	such	as	Th9,	Th17,	and	Th22	cells,	
also	play	partial	roles	in	inflammation,	mucus	production,	and	tissue	healing.	Smooth	muscle,	myofibroblast	activation,	and	bronchial	
hyperreactivity	are	related	to	IL‐4,	IL‐9,	IL‐13,	IL‐25,	and	IL‐33.	Several	chemokines,	and	arachidonic	acid	pathway	molecules	and	other	small	
molecules	play	roles	in	the	inflammatory	cell	recruitment	and	further	augmentation	of	the	inflammatory	cascades.	Treg	and	Breg	cells	play	a	
role	on	control	of	inflammation	and	extensive	cellular	activation	by	using	IL‐10	and	TGF‐β	as	well	as	many	other	suppressive	mechanisms
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2.2 | Mechanisms of type 2 inflammation and 
immune tolerance to allergens
2.2.1 | Type 2 immune response
Since	the	discovery	of	T‐helper	(Th)	subsets,	it	was	demonstrated	in	
the	last	three	decades	that	almost	all	immune	cells	display	functional	
subsets	characterized	by	distinct	signature	cytokines	and	surface	re‐
ceptors.	Generally,	 it	 is	considered	that	a	type	2	 immune	response	
is	 the	 main	 player	 in	 the	 pathogenesis	 of	 eosinophilic	 asthma,	 al‐
lergic	 rhinitis,	 chronic	 rhinosinusitis	with	nasal	 polyps,	 eosinophilic	
esophagitis,	 and	 extrinsic	 atopic	 dermatitis.40	 The	 type	 2	 immune	
response	 is	 an	 immune	 response	 to	 environmental	 noninfectious	
proteins	and	helminths,	and	involves	Th2	cells,	type	2	B	cells,	group	
2	innate	lymphoid	cells,	type	2	macrophages,	a	small	fraction	of	IL‐4–
secreting	NK	cells,	IL‐4–secreting	NK‐T	cells,	basophils,	eosinophils,	
and	mast	cells.41,42	From	a	complex	network	of	cytokines,	IL‐4,	IL‐5,	
IL‐9,	IL‐13,	and	IL‐31	are	mainly	secreted	from	immune	system	cells	
and	 IL‐25,	 IL‐33,	 and	 TSLP	 from	 tissue	 cells,	 particularly	 epithelial	
cells.43,44	 (Figure	 1)	 GATA3	 is	 the	 key	 transcription	 factor	 for	 the	
induction	of	 this	 response.45	Both	 the	 innate	and	 the	adaptive	 im‐
mune	response	contribute	to	type	2	immune	response.	Among	these	
cytokines,	IL‐4	and	IL‐13	play	roles	in	production	of	allergen‐specific	
IgE,	IL‐5	in	eosinophilia,46,47	IL‐9	and	IL‐13	in	mucus	production,	IL‐4	
and	IL‐13	in	tissue	migration	of	Th2	cells	and	eosinophils,	and	IL‐4	and	
IL‐13	in	regulation	of	tight	junctions	and	epithelial	barrier	integrity.48 
Type	1,	type	17,	type	22,	and	immune	regulatory	responses,	and	non‐
allergic	 mechanisms	 such	 as	 environmental	 factors,	 psycho‐social	
stress,	activation	of	metabolic	pathways,	resident	cells	in	the	remod‐
eled	phenotype,	or	epithelial	barrier	dysfunction	 further	modulate	
the	profile	of	type	2–driven	inflammation.	In	addition,	type	2–driven	
inflammation	 is	characterized	by	a	high	cellular	plasticity	 that	ena‐
bles	the	cells	to	adapt	to	a	specific	inflammatory	milieu.	Several	sub‐
endotypes	might	exist	within	the	type	2	immune	response	complex	
endotype	 such	 as	 the	 IL‐5‐high,	 IL‐13‐high,	 or	 IgE‐high	 endotype,	
and	 their	 dominance	 differs	 between	 allergic	 diseases	 (Figure	 1).	
Omalizumab	 targeting	 IgE,	mepolizumab,	 reslizumab	 targeting	 IL‐5,	
benralizumab	 targeting	 the	 IL‐5	 receptor,	 and	 dupilumab	 targeting	
the	IL‐4	and	IL‐13	common	receptor	alpha	chain	are	some	of	the	bio‐
logicals	currently	available	to	control	type	2	inflammation.
2.2.2 | T‐regulatory and B‐regulatory cells
Immune	regulation	is	an	important	function	of	the	immune	system	
to	 tolerate	 self‐tissues	 and	 non–self‐environmental	 allergens.	 T‐
regulatory	(Treg)	cell	subsets	have	distinct	phenotypes	and	include	
constitutive	and	inducible	subsets	of	CD4+CD25+ Forkhead	box	P3	
(FOXP3)+	Treg	cells	and	type	1	Treg	cells	 (Tr1).	As	a	second	major	
player	 in	 immune	 regulation,	 IL‐10–producing	 B‐regulatory	 (Breg)	
cells	have	also	been	demonstrated	to	suppress	allergen‐specific	re‐
sponses	and	promote	IgG4	isotype	antibodies.49	Allergen	tolerance	
in	high‐dose–exposed	individuals	such	as	beekeepers	and	cat	own‐
ers,	the	AIT	response,	and	protective	effects	of	farm	exposure	make	
up	one	of	the	most	representative	areas	where	Treg	and	Breg	cells	
Unknowns and future research highlights in type 2 im-
mune response
•	 Which	cell	is	more	critical	and	predominant	for	general	type	
2	responses,	and	in	which	disease?
•	 Which	cytokine	is	more	important	for	which	clinical	in	vivo	
situation?
•	 A	detailed	list	of	environmental	factors	that	enhance	type	2	
responses
•	 Mechanisms	 of	 viral	 infections	 in	 exacerbation	 of	 type	 2	
diseases
•	 Local	 immune	 deficiency	 caused	 by	 a	 type	 2	 immune	
response
•	 Effect	of	type	2	immune	responses	to	chronicity
•	 Novel	 biomarkers	 of	 type	 2	 responses	 for	 treatment	 se‐
lection,	to	decide	when	to	stop	treatment	and	to	monitor	
therapy	response	in	type	2	diseases
•	 Role	of	epithelial	barrier	leakiness	in	the	development	and	
chronicity	 of	 complex	 type	 2	 immune	 response–related	
diseases
•	 Head‐to‐head	comparison	of	different	 type	2	 immune	re‐
sponse‐targeting	treatments
•	 Pharmacoeconomics	of	different	type	2	immune	response‐
targeting	 treatments	 in	comparison	with	existing	conven‐
tional	treatments
•	 Disease‐modifying	 effect	 of	 different	 type	 2	 immune	 re‐
sponse‐targeting	treatments
•	 Combination	treatments	with	allergen	immunotherapy
Unknowns and future research highlights in Treg and 
Breg response
•	 Life	span	of	allergen	immunotherapy	and	natural	exposure‐
induced	Treg	and	Breg	cells	in	vivo
•	 Effect	of	Treg	and	Breg	cells	on	tissue	cells
•	 Functional	 comparison	 of	 different	 subsets	 of	 Treg	 and	
Breg	cells
•	 Molecular	mechanisms	of	Treg	and	Breg	cell	generation	in	
vivo
•	 Adjuvants	that	promote	Treg	and	Breg	cells	in	vivo
•	 Relationship	 of	 resident	 tissue	 cells	 and	 their	 interaction	
with	 Treg	 and	 Breg	 cells	 in	 allergen	 immunotherapy‐in‐
duced	immune	tolerance
•	 Early	biomarkers	and	predictors	for	the	generation	of	Treg	
and	Breg	responses
•	 Mechanisms	 of	 long‐term	 maintenance	 of	 allergen	 toler‐
ance	and	the	link	to	Treg	and	Breg	responses
•	 Mechanisms	of	inducing	high‐affinity	IgG4	and	low‐affinity	
IgE	antibodies
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display	their	major	roles.49‐51	IL‐10,	IL‐35,	and	TGF‐beta	are	the	major	
suppressor	cytokines	with	immune	regulatory	functions	within	mul‐
tiple	complex	mechanisms.42,50,52	Different	 subsets	have	been	de‐
fined	 in	 different	 disease	 conditions,	 and	 research	 should	 further	
identify	their	regulation	and	in	vivo	relevance.53	T‐	and	B‐regulatory	
cells	suppress	many	functions	of	type	2	inflammation	including	type	
2	innate	lymphoid	cells.54	Extensive	research	is	ongoing	in	this	area.	
To	date,	there	are	no	biologicals	that	induce	T‐	and	B‐regulatory	re‐
sponses	in	patients;	however,	various	modes	of	AIT	represent	major	
stimulators	of	these	cells	in	an	allergen‐specific	manner	in	vivo.
2.3 | Neuroimmune mechanisms in allergic 
inflammation
It	is	becoming	increasingly	clear	that	immune	cells	do	not	act	alone	
and	 that	 cross	 talk	 and	 reciprocal	 regulation	 between	 neural	 and	
immune	 systems	 are	 essential	 in	 the	 pathophysiology	 of	 allergic	
diseases	including	allergic	asthma,	atopic	dermatitis,	and	food	aller‐
gies.55,56	 Immune	and	neuronal	 cell	 types	are	 found	 in	 large	num‐
bers	at	 skin	and	mucosal	barrier	 surfaces	and	are	 in	close	contact	
with	 each	 other	 forming	 a	 neuronal‐immune	 cell	 network.57‐60 
Both	immune	and	neural	cells	detect	and	respond	to	environmental	
threats	and	harmful	stimuli	including	allergens.	Innate	and	adaptive	
immune	 responses	 mediate	 proinflammatory	 responses	 by	 secre‐
tion	of	cytokines	(eg,	IL‐4,	IL‐5,	IL‐9.	IL‐13,	IL‐25,	IL‐31,	IL‐33,	TSLP),	
chemokines	 (eg,	 histamine),	 and	 other	 lipid	 mediators	 (eg,	 leukot‐
rienes)	 on	 encountering	 allergens.	Within	 these	 cytokines,	 a	 bio‐
logical	targeting	IL‐31	was	shown	to	treat	itch	in	atopic	dermatitis.	
In	 addition	 to	mediating	 allergic	 responses	 via	 immune	 responses,	
these	proinflammatory	mediators	also	directly	activate	sensory	neu‐
rons	 that	 regulate	 itch,	 cough,	 sneezing,	 bronchoconstriction,	 and	
alterations	in	gastrointestinal	motility.59
On	stimulation,	sensory	and	autonomic	neurons	release	neuro‐
peptides	and	neurotransmitters	such	as	substance	P,	neurokinin	A,	
neuromedin	U	 (NMU),	 calcitonin	 gene–related	 peptide,	 vasoactive	
intestinal	peptide,	acetylcholine,	and	norepinephrine	that	signal	im‐
mune	cells.55	 In	 the	airways,	 calcitonin	gene–related	peptide	 is	 re‐
leased	by	sensory	nerves,	which	has	been	shown	to	inhibit	dendritic	
cell	maturation	and	allergen‐specific	T‐cell	 responses.61	 In	 the	gut,	
ILC2	cells	were	shown	to	express	Nmur1,	a	receptor	for	the	neuro‐
peptide	NMU.	ILC2s	live	in	close	proximity	to	NMU‐producing	nerve	
F I G U R E  2  The	exposome:	The	exposome	includes	the	entire	environmental	exposures	of	an	individual	from	conception	throughout	the	
whole	life.	Early‐life	events	such	as	mode	of	delivery,	breastfeeding,	mother's	diet,	lifestyle	and	health	status,	antibiotics,	and	other	drug	
usage	in	pregnancy	and	early	childhood,	early‐life	environment	(ie,	siblings,	pets	at	home,	proximity	to	farm	animals	and	green	areas,	usage	
of	primary	farm	products)	can	significantly	influence	the	epigenetic	regulation	of	immune	system	and	tissue	cells
Future prospects for research on neuroimmune regu-
lation of allergic diseases
•	 The	 mechanisms	 underlying	 allergen‐induced	 release	 of	
proinflammatory	mediators	and	neural	activation	(reflexes)
•	 Colocalization	 and	 direct	 and	 local	 communications	 be‐
tween	neuronal	and	immune	cells	and	their	role	in	mediat‐
ing	allergic	response	and	tolerance
•	 Identification	of	neuropeptides	and	neurotrophins	that	di‐
rectly	act	on	immune	cells	via	receptors
•	 Development	 of	 pharmacological	 compounds	 targeting	
neuropeptides	 and	 neurotrophins	 that	 mediate	 allergic	
response
•	 Feedback	loop	between	neuronal	and	immune	cells	in	medi‐
ating	immune	homeostasis
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cells	and	become	proinflammatory	when	exposed	to	NMU.	NMU	sig‐
naling	can	significantly	amplify	allergic	inflammation	when	high	levels	
of	IL‐25,	IL‐33,	and	TSLP	are	present.62	In	a	mouse	model	of	allergic	
asthma,	 norepinephrine	was	 found	 to	 stimulate	 IgE	 production	on	
binding	β2‐adrenergic	receptors	and	activating	B	cells.63,64	A	positive	
feedback	 loop	 between	 neurotransmitters	 and	 neuropeptides	 and	
immune	cells	exists.	However,	our	understanding	of	 these	 interac‐
tions	and	the	signals	that	mediate	their	responses	to	the	ever‐chang‐
ing	physiological	and	pathological	conditions	is	still	very	limited.
2.4 | Exposome, environmental factors and allergy
The	rising	trend	in	allergies	is	associated	with	changes	in	lifestyle	
and	the	control	of	infections	which,	taken	together,	seem	to	result	
in	an	“under‐challenged”	immune	system.65,66	On	the	other	hand,	
lifestyle	 changes	 and	 indoor	 and	 outdoor	 environmental	 pollut‐
ants67‐69	are	suspected	to	keep	our	immune	system	in	a	constant	
state	 of	 low‐grade	 inflammation.	 Apart	 from	 direct	 effects	 of	
outdoor	pollutants	on	humans,	pollen‐producing	plants	are	them‐
selves	 subject	 to	 modification	 by	 anthropogenic	 pollutants.70,71 
Presumably,	beneficial	factors	include	growing	up	in	a	rural	envi‐
ronment,	traditional	lifestyle,	and	a	nutrition	rich	in	dietary	fibers	
and	of	a	high	diversity.	It	has	become	evident	that	environmental	
factors	 induce	 epigenetic	 changes	which	 are	 associated	with	 al‐
lergic	diseases	(summarized	in	Ref.72).
The	exposome	includes	the	entire	environmental	exposures	that	
a	 person	 experiences,	 from	 conception	 throughout	 the	 whole	 life	
(Figure	2).73	A	 clear	missing	 knowledge	 is	 the	 lack	of	 thorough	ep‐
idemiological	 studies	 encompassing	 a	 holistic	 approach	with	 expo‐
some	and	reactome	(response	patterns)	over	a	life	span.	This	wide	gap	
further	 opens	 especially	 because	 validated	methods	 for	 exposome	
assessment,	especially	the	personal	one,	are	lacking.	Furthermore,	a	
clear	bias	emerges	 since	biogenic	and	anthropogenic	pollutants	are	
measured	outdoors	while	people	spend	a	considerable	part	of	their	
lives	indoors.	The	research	focus	in	environmental	health	and	allergy	
should	therefore	be	to	study	the	impact	of	indoor	and	outdoor	pol‐
lutants	focusing	on	the	role	of	combined	exposures	to	air	pollution,	
microclimate,	green	spaces,	and	allergens.	Innovative	approaches	to	
characterize	environmental	exposures	including	satellite	data	and	sta‐
tionary	and	personal	monitoring	should	be	developed.74	This	further	
requires	the	development	of	new	informatics	tools	and	data	analytics	
to	analyze	the	large	and	complex	generated	datasets.	The	aim	should	
be	to	understand	the	impact	of	environment	through	the	entire	 life	
span	on	the	complete	disease	spectrum	to	unravel	the	interaction	of	
the	environment	with	the	barrier	organs	including	their	microbiomes,	
the	immune	system,	and	the	whole	body.	Climate	change	exhibits	di‐
rect	 and	 indirect	effects	on	human	health–related	aspects.	Climate	
variability	 modifies	 the	 abundance	 and	 occurrence	 of	 plants	 and	
fungi,	noticeably	those	with	high	allergological	importance.	The	effect	
of	climate	change	on	human	health	is	both	a	threat	and	foremost	a	re‐
search	focus	especially	in	the	field	of	allergy.	A	thorough	understand‐
ing	of	the	molecular	mechanisms	of	the	interactions	of	environment	
with	the	human	body	but	also	environment‐environment	interactions	
will	enable	us	to	develop	prevention	strategies	for	allergies.
2.5 | Role of the microbiome and diet in 
immune responses
Enormous	varieties	of	microbes	colonize	the	skin	and	mucosal	body	
surfaces.	These	microbes	are	organized	within	complex	community	
structures,	whose	composition	is	dependent	on	the	specific	body	site	
examined.	It	is	increasingly	appreciated	that	the	microbiome	interacts	
intimately	with	mucosal	immune	processes	and	disrupted	communica‐
tion	between	the	microbiome	and	the	host	due	to	altered	microbiome	
composition	and/or	metabolism	is	thought	to	negatively	influence	im‐
mune	homeostatic	networks	and	may	play	a	role	in	immune	hypersen‐
sitivity	to	environmental	exposures,	such	as	allergens.75
A	 number	 of	 studies	 have	 consistently	 demonstrated	 that	 an	
altered	gut,	 lung,	nasal,	or	skin	microbiome	is	associated	with,	and	
sometimes	precedes,	allergic	sensitization	and	inflammation.76,77 In 
particular,	early‐life	events	such	as	mode	of	delivery,	breastfeeding,	
mother's	diet	and	health	status,	antibiotics,	and	other	drug	usage	in	
pregnancy	and	early	childhood,	early‐life	environment	 (ie,	 siblings,	
pets	at	home,	proximity	to	farm	animals	and	green	areas,	usage	of	
primary	farm	products)	can	significantly	influence	the	timing	of	bac‐
terial	colonization	and	establishment.78‐80	However,	one	of	the	most	
potent	modulators	of	microbiota	composition	 is	diet,	as	consumed	
foods	provide	 the	 fuel	 for	microbial	metabolic	activities.81	For	ex‐
ample,	 microbiota‐accessible	 carbohydrates	 (MAC)	 are	 complex	
carbohydrates	found	in	dietary	fibers	that	contribute	to	microbial	di‐
versity	and	generation	of	metabolites,	such	as	short‐chain	fatty	acids	
(SCFAs).82	SCFAs	promote	regulatory	 immune	responses,	and	high	
SCFA	levels	early	in	life	are	associated	with	protection	from	atopic	
sensitization.83	In	contrast,	a	high‐fat	diet	is	associated	with	negative	
effects	on	microbiota	composition	and	metabolism.
Despite	 increasing	 awareness	 of	 the	 importance	 of	 microbi‐
ome‐diet	interactions	in	health	and	disease,	the	molecular	basis	for	
these	multidirectional	functional	interactions	is	only	beginning	to	be	
Hot spots in environmental health research
•	 Moving	 from	 associations	 to	 causalities	 and	 molecular	
mechanisms
•	 Understanding	 environment‐gene	 interactions	 and	 espe‐
cially	the	role	of	epigenetic	changes
•	 Develop	innovative	methods	for	exposome	assessment,	es‐
pecially	the	personal	one
•	 Development	 of	 devices	 for	 personal	 monitoring	 of	 real‐
time	 pollen	 and	 fungal	 spore	 abundance	 spatiotemporal	
information
•	 Understanding	additive	and	summative	effects	of	environ‐
mental	factors	on	health	and	disease
•	 Define	personal	 thresholds	 for	environmental	 triggers	 for	
allergic	symptoms
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described.	Although	diet‐microbiome	interventions	are	exciting	and	
attractive	approaches,	many	unknown	factors	still	limit	the	success‐
ful	translation	of	these	potentially	game‐changing	interventions	into	
the	clinic.
2.6 | Respiratory viral infections and allergy
Respiratory	viruses	are	the	most	common	causes	of	respiratory	dis‐
eases,	which	can	be	linked	with	the	potentiation	of	acute	and	chronic	
respiratory	 mucosal	 inflammation.	 This	 usually	 occurs	 through	
mechanisms	 including	 upregulation	 of	 cell	 adhesion	 molecules,	
pathogen	sensing	receptors,	and	Toll‐like	receptors,	which	are	com‐
mon	immunopathogenic	factors	mediating	or	involved	in	virus‐	and	
allergen‐induced	mucosal	inflammation.84‐91	In	addition,	respiratory	
viruses	were	 suggested	 to	 impact	 cilia	 and	 tight	 junction	 integrity	
in	airway	epithelial	cells	through	the	modulation	of	ZO‐1,	claudin‐1,	
and	occludin	in	the	airway	epithelial	barrier,92‐94	which	may	be	linked	
to	pathophysiology	of	airway	diseases.	The	nasal	epithelium	is	the	
primary	portal	of	entry	for	respiratory	viruses	and	immediate	target	
for	viral	replication	in	the	airways.87,95	It	is	also	an	active	component	
of	 initial	 host	 responses	against	 viral	 infection.	 Such	nasal	 epithe‐
lial‐specific	 transcriptomic	 alterations	 may	 significantly	 influence	
the	downstream	immune	responses	and	homeostasis	that	define	the	
pathology	of	respiratory	 infection	and	complications.87,95‐97	This	 is	
evident	in	the	case	of	most	respiratory	viral	infections,	which,	while	
self‐limiting,	 could	 trigger	 chronic	 type	 2	 inflammatory	 responses	
via	excessive	release	of	chemokines	and	cytokines	into	the	airways.	
The	 resulting	 recruitment	of	 the	 immune	cells	 (ie,	neutrophils,	eo‐
sinophils,	mast	cells,	and	T	cells)	may	then	ultimately	predispose	the	
airway	to	remodeling.98‐101	In	addition,	a	recent	study	showed	that	
H3N2	infection	of	the	nasal	epithelium	was	associated	with	signifi‐
cant	 increase	 in	 interferons	 (IFN‐α,	 IFN‐γ,	 IL‐29),	 proinflammatory	
cytokines	 (TNF‐α,	 BDNF,	 IL‐3),	 and	 viral‐associated	 chemokines	
(IP‐10,	MCP‐3,	I‐TAC,	MIG),	detectable	as	early	as	24	hours	postin‐
fection.102	This	translates	into	rapid	monocyte,	NK‐cell,	and	innate	
T‐cell	 (MAIT	and	γδ	T	cells)	activation,	evident	with	CD38+	and/or	
CD69+	upregulation.102	Therefore,	an	understanding	of	the	predom‐
inant	type	and	underlying	mechanisms	of	mucosal	inflammation	trig‐
gered	by	common	viral	infections	will	allow	identification	of	targets	
for	better	management	of	chronic	airway	inflammatory	diseases.
3  | DIAGNOSTIC CHALLENGES AND 
REGUL ATORY CONSIDER ATIONS
3.1 | Clinical trials for the treatment of allergic 
diseases
In	 2008,	 the	 Committee	 for	 Medicinal	 Products	 for	 Human	 Use	
(CMPH)	of	the	European	Medicine	Agency	(EMA)	has	implemented	
the	“Guideline	on	the	Clinical	Development	of	Products	for	Specific	
Immunotherapy	 for	 the	 Treatment	 of	 Allergic	 Diseases	 (CHMP/
EWP/18504/2006)”	 (Available	 from:	 http://www.ema.europa.eu/
docs/en_GB/docum	ent_libra	ry/Scien	tific_guide	line/2009/09/
WC500	003605.pdf	 and	 ref.103)	 and	 by	 this	 has	 set	 methodologi‐
cal	 standards	 for	 clinical	 trial	 designs	 for	AIT	 regarding	phase	 I‐III	
performances	 and	 outcomes.	 This	 guidance	 has	 been	 followed	 in	
“Therapy	Allergen	Ordinance	(TAO)”	which	has	been	initiated	for	fu‐
ture	registration	and	marketing	authorization	in	Germany	of	a	group	
of	allergen	extracts	of	specific	species	(details	in	Ref.104).	An	increas‐
ing	number	of	AIT	products	fulfill	the	regulatory	demands	and	have	
been	authorized	 in	different	countries	on	the	basis	of	proven	effi‐
cacy	 in	 the	 clinical	 documentation.105,106	However,	 the	 regulatory	
guidance	leaves	some	space	for	interpretation	regarding	certain	spe‐
cificities	of	clinical	trial	design	in	both	early	and	late	phases	of	clinical	
development	programs	for	AIT,	and	harmonization	of	methodologi‐
cal	principles	 in	 the	design	of	 these	 trials	would	be	preferable	 for	
all	 parties	 involved.107	 Hence,	 the	 Immunotherapy	 Interest	 Group	
(IT‐IG)	of	the	European	Academy	of	Allergy	and	Clinical	Immunology	
(EAACI)	has	elaborated	different	 task‐force	projects	 regarding	 im‐
provement	 of	 methodological	 study	 design	 in	 AIT	 (https	://www.
eaaci.org/organ	isati	on/eaaci‐inter	est‐group	s/ig‐on‐immun	other	
apy/activ	ities/	2880‐task‐forces‐of‐the‐immun	other	apy‐inter	est‐
group.html;	accessed	on	07	Dec	2018).	In	an	EAACI	Position	Paper,	
Unknowns in the microbiome area for future research
•	 Contribution	of	the	virome	(viral	communities)	and	mycobi‐
ome	(fungal	communities)	to	immune	tolerance	networks
•	 Mechanistic	pathways	 linking	diet	diversity,	microbial	me‐
tabolism,	and	allergy	prevention
•	 Role	of	the	diet	 in	modulating	microbial	communities	out‐
side	of	the	gut
•	 The	importance	of	baseline	microbial	populations	or	histori‐
cal	dietary	patterns	in	determining	the	response	to	micro‐
biota	or	diet‐based	interventions
•	 The	influence	of	microbiota	on	the	clinical	response	to	al‐
lergen‐specific	immunotherapy	and	its	mechanisms
•	 Definition	of	a	healthy	microbiota	and	ways	to	achieve	it
•	 Possibility	of	intervention	in	the	microbiome	of	a	diseased	
individual
Unknowns and future prospects for research in viral 
infections and allergic diseases
•	 The	predominant	type	and	underlying	mechanisms	of	mu‐
cosal	inflammation	(eg,	type	2	or	non‐type	2)	triggered	by	
infection	of	different	types	of	respiratory	viruses
•	 Mechanistic	role	of	viral	infections	in	chronicity
•	 Mechanisms	of	viral	infections	in	exacerbations
•	 Mechanisms	 of	 viral	 infections	 in	 breaking	 of	 allergen	
tolerance
•	 Novel	mechanisms	to	prevent	or	avoid	viral	infections
•	 Novel	vaccines	for	various	viruses
•	 Novel	 anti‐viral	 treatments	 based	 on	 newly	 identified	
mechanisms
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this	group	has	aimed	to	summarize	and	standardize	clinical	endpoint	
measures	and	has	elaborated	a	combined	symptom	and	medication	
score	(CSMS)	as	standard	primary	endpoint	for	future	(pivotal)	trials	
in	AIT.108	Another	example	is	an	EAACI	Position	Paper,	which	over‐
views	current	concepts	in	tolerance‐inducing	mechanisms	aimed	to	
highlight	potential	biomarkers	which	may	be	of	predictive	value	for	
determining	responders	to	AIT	in	clinical	trials.15	However,	there	is	
an	urgent	need	for	further	harmonization	and	clinical	validation	of	
methodological	determinants	in	AIT	clinical	study	design,	which	can	
only	be	achieved	by	 international	 collaboration	of	 clinical	 experts,	
methodologists,	and	regulatory	authorities.109,110
3.2 | Precision medicine and immune monitoring of 
allergic diseases
Precision	medicine	(providing	the	right	treatment	to	the	right	patient	
and	the	right	dose	at	the	right	time)	requires	an	accurate	diagnosis	
and	monitoring	of	the	treatment	response.	While	precision	medicine	
has	been	practiced	in	allergology	for	over	a	century	since	the	advent	
F I G U R E  3  Precision	medicine:	Precision	medicine	requires	the	network	of	knowledge	from	both	biomedical	and	clinical	research.	It	
includes	all	of	the	omics	areas	and	exposome	from	molecular	characterization	and	biomarker	development	to	electronic	health	records,	and	
clinical	discoveries	in	diagnosis	and	treatment.	The	introduction	of	a	new	taxonomy	is	needed	to	ensure	that	all	the	stakeholders	speak	the	
same	language
Examples of unknowns and future prospects for har-
monization of AIT trial design and interpretation of 
trial results (modified to references107,109,110)
•	 Evaluation	and	validation	of	possible	biomarkers	of	predic‐
tive	value	for	efficacy15
•	 Further	 validation	of	 clinical	meaningful	 primary	 and	 sec‐
ondary	endpoints108
•	 Clinically	 justified	definitions	of	 relevant	 treatment	effect	
sizes
•	 Potential	 of	 allergen	 exposure	 chambers	 for	 AIT	 product	
development107
•	 Minimal	level	of	evidence	needed	for	the	clinical	documen‐
tation	of	efficacy	in	the	pediatric	population110
•	 Better	understanding	of	placebo	effects	in	SCIT	and	SLIT107
•	 Defining	clinical	endpoints	and	establishing	the	effective‐
ness,	 disease‐modifying	 properties,	 and	 the	 duration	 of	
both	in	asthmatic	patients
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of	grass	pollen‐specific	immunotherapy,111	it	currently	infers	(often	
synonymous	with	“personalized	medicine”)	use	of	the	new	“omics”	
technologies	to	identify	genes	or	biomarkers	for	diagnosis	or	moni‐
toring	of	treatment	efficacy	(Figure	3).13,112	The	“omics”	revolution	is	
based	on	platform	technologies	in	genomics	(by	far	the	most	robust),	
metabolomics,	 proteomics,	 epigenomics,	 transcriptomics,	 lipidom‐
ics,	and	microbiomics	to	generate	vast	global	datasets,	and	advanced	
bioinformatics	 to	 interrogate	and	 interpret	 the	datasets	using	ma‐
chine	 learning	and	artificial	 intelligence	 (Figure	4).113	Such	analysis	
of	population‐based	datasets	can	reveal	novel	insights	to	underpin	
therapeutic	 selection	 from	 an	 expanded	 range	 of	 precise	 biologi‐
cals.114	Examples	are	emerging	from	patients	with	inborn	errors	of	
immunity	 (IEI)	 in	whom	the	genetically	defined	defect	can	be	spe‐
cifically	 targeted	with	 therapeutics.115,116	 The	 functional	 utility	 of	
data	from	the	omics	platforms	will	be	further	enhanced	by	the	pub‐
lic	release	of	omics	datasets	including	Genotype‐Tissue	Expression	
(GTEx)117	and	Encyclopaedia	of	DNA	Elements	(ENCODE).118
Technological	 advances	 in	 immune	 monitoring	 capability	 are	
augmented	by	highly	standardized	or	chimeric	recombinant	allergens	
and	peptides	(B‐	and	T‐cell	epitope‐based).	Exponential	advances	in	
microarrays,	 time‐of‐flight	 mass	 cytometry	 (CyTOF),	 basophil	 ac‐
tivation	 tests,	 next‐generation	gene	 sequencing,	 and	RNA‐seq	are	
generating	huge	enabling	datasets.15,115,116,119‐123	The	risk	that	small	
populations	 of	 highly	 pathogenic	 cells	 might	 be	masked	 by	 abun‐
dant	signatures	of	more	frequent	or	more	active	cells	 is	combated	
by	the	emergence	of	enhanced	single	B‐	and	T‐cell	 immunopheno‐
typing	using	flow	cytometry–based	assays.	This	allows	longitudinal	
immunoprofiling	 of	 relevant	 cell	 subsets	 in	 individuals	 before	 and	
during	AIT.	Better	dissection	of	mechanisms	underlying	allergic	dis‐
eases	informs	better	tailoring	of	therapies.115,116,119‐122,124,125
3.3 | Allergic rhinitis and nonallergic rhinitis
Chronic	 rhinitis	 (CR)	 is	 one	 of	 the	most	 common	 diseases	 glob‐
ally,	with	a	considerable	financial	burden.126,127	At	present,	CR	is	
Unmet needs in precision medicine
•	 Consensus	on	endotypes	and	clinically	applicable	biomark‐
ers	for	distinct	allergic	disorders
•	 Accurate	targeted	activity;	even,	widespread	or	specific	as	
needed
•	 Increased	availability	of	oral	formulations:	solid	or	liquid
•	 More	favorable	dosing	intervals
•	 Minimization	 of	 adverse	 side	 effects	 (especially	 anaphy‐
lactic/allergic	 reactions,	 antibody	 induction,	 complement	
activation)
•	 Economic	feasibility	enhancement
•	 Determination	of	long‐term	effects
•	 “Large	 dataset”	 protection	 and	 interpretation,	 including	
ethical	considerations
•	 Development	of	a	precision	medicine‐specific	nomenclature
•	 Development	of	treatment	and	diagnostic	algorithms
•	 Development	of	precision	medicine–focused	guidelines
F I G U R E  4  Omics:	The	omics	
revolution	was	one	of	the	major	driving	
forces	of	recent	developments	that	
enabled	investigation	of	almost	everything	
at	the	molecular	level	of	proteins,	
lipids,	and	small	molecules	including	
innumerable	DNA	and	RNA	sequencings	
with	a	hypothesis‐free	approach
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simplistically	subclassified	as	allergic	rhinitis	(AR)	and	nonallergic	
rhinitis	 (NAR).128	Although	phenotyping	of	rhinitis	has	 important	
consequences	in	the	treatment	of	the	entity,129	the	presently	em‐
ployed	phenotypes	cannot	meet	the	needs	of	precision	medicine;	
suggesting	an	urgent	need	for	the	CR	phenotypes	to	be	updated	
with	the	progress	of	diagnostic	methods.	In	this	regard,	Meng	and	
colleagues	have	recently	investigated	the	phenotypes	of	CR	based	
on	a	 cluster	 analysis	of	12	 clinical	 variables.130	 In	 this	 study,	AR	
was	subclassified	as	allergic	rhinitis	with	or	without	asthma,	while	
NAR	was	subclassified	as	nonallergic	rhinitis	with	eosinophilia	syn‐
drome	(NARES)	without	asthma,	NARES	with	asthma,	local	allergic	
rhinitis	(LAR),	and	idiopathic	rhinitis.	The	finding	of	the	LAR	clus‐
ter	was	interesting	because	none	of	these	patients	had	a	history	
of	asthma,	but	demonstrated	high	 levels	of	 local	eosinophils	and	
local	production	of	specific	IgE	(local	IgE),	of	which	the	latter	has	
been	used	in	studies	of	LAR	over	the	last	few	years.131‐133	Indeed,	
another	 study	 by	Meng	 and	 colleagues	 has	 suggested	 that	 local	
IgE	is	a	reliable	noninvasive	alternative	to	serum	IgE	for	the	diag‐
nosis	of	AR,134	and	there	is	emerging	evidence	that	local	IgE	could	
also	be	used	instead	of	nasal	allergen	provocation	test	(NAPT)	for	
the	 diagnosis	 of	 LAR.	 Besides	 local	 IgE,	 nasal	 cytology	 has	 also	
been	shown	to	be	useful	in	the	diagnosis	of	CR	A	recent	study	by	
She	and	colleagues	assessed	nasal	cytology	in	chronic	sinusitis	pa‐
tients	with	rhinitis,	using	the	liquid‐based	ThinPrep	Cytology	Test	
(TCT)	and	demonstrated	that	this	technique	has	higher	sensitivity,	
specificity,	 and	 positive	 predictive	 value	 for	 inflammation	 in	 the	
inferior	turbinates	than	for	inflammation	in	the	maxillary	sinus.135 
Thus,	the	TCT	might	also	be	used	in	the	studies	on	CR,	especially	
NARES.
In	 conclusion,	 there	 is	 increasing	 evidence	 that	 local	 IgE	 and	
nasal	cytology	are	useful	clinical	diagnostic	markers	in	CR	and	might	
represent	the	way	forward	especially	for	studies	differentiating	the	
endotypes	of	AR	and	NAR	in	the	future.
3.4 | New approaches to the diagnosis and 
treatment of drug hypersensitivity reactions
Drug	 hypersensitivity	 reactions	 (DHRs)	 are	 defined	 as	 adverse	
effects	 of	 pharmaceutical	 formulations	 that	 clinically	 resemble	
allergy.	Drug	 allergies	 are	 defined	 as	DHRs	 for	which	 a	 definite	
immunological	 mechanism,	 IgE‐	 or	 T	 cell–mediated,	 is	 demon‐
strated.136	DHRs	constitute	an	important	health	problem,	affect‐
ing	more	than	7%	of	the	population,	137	for	whom	drugs,	such	as	
beta‐lactam	antibiotics	and	nonsteroidal	anti‐inflammatory	drugs,	
are	 essential	 for	 treatment	 of	 common	diseases.138,139	Based	on	
the	 clinical	 characteristics	 of	 DHRs,	 different	 phenotypes	 have	
been	identified,137	although	the	lack	in	understanding	the	under‐
lying	mechanisms	of	many	DHRs	has	hampered	the	definition	of	
endotypes	and	identification	of	biomarkers.140,141
The	classification	of	DHRs	based	on	the	time	elapsed	between	
drug	administration	and	development	of	symptoms	is	still	a	matter	of	
debate,	because	it	is	difficult	to	establish	a	cutoff	point	to	distinguish	
between	 immediate	 and	 nonimmediate	DHRs.13,136,141	 These	 data	
are	 relevant	 for	defining	phenotypes	 and	establishing	 an	 accurate	
diagnosis	and	specific	treatment.	An	important	recent	advance	has	
been	the	inclusion	of	“Drug	hypersensitivity”	as	a	subsection	in	the	
International	Classification	of	Diseases	(ICD)‐11.140
The	 diagnosis	 of	 DHR	 is	 mainly	 based	 on	 skin	 tests	 and	 drug	
provocation	tests,	methods	that	are	not	free	of	risk,	still	 lack	stan‐
dardization,	and	differ	depending	on	the	drug,	mechanisms,	and	even	
the	health	system.142‐144	There	is	an	urgent	need	for	developing	new	
in	vitro	diagnostic	tests	or	improving	those	already	existing,138	such	
as	basophil	activation	test,145,146	to	improve	the	diagnostic	workup.	
The	complexity	of	DHR	diagnosis	and	its	lack	of	optimal	specificity	
lead	to	an	over‐diagnosis.	This	is	an	important	problem,	as	patients	
“labeled”	as	allergic	 receive	alternative	treatments	 that	are	usually	
less	effective	and	more	 toxic,	 so	 “de‐labeling”	constitutes	a	public	
health	measure.147	Primary	care	physicians	are	often	the	first	point	
of	contact	for	patients	with	DHRs;	thus,	they	have	a	key	role	in	diag‐
nosis	and	need	specific	training.148
Although	the	specific	treatment	of	DHRs	is	avoiding	the	drug	in‐
volved	and	those	chemically	related,	desensitization	is	nowadays	a	
frequent	option.149‐151	In	that	sense,	rapid	drug	desensitization	is	a	
cost‐effective	 technique	 that	 activates	 inhibitory	mechanisms	 and	
permits	 patients	 to	 receive	 the	 first‐choice	 medications	 to	 which	
they	are	allergic.149,150
Research needs for DHRs
•	 The	prevalence	and	incidence	of	DHRs
•	 Underlying	mechanisms	of	DHRs
•	 The	most	adequate	classification	of	DHRs
•	 Definition	of	endotypes	and	biomarker	identification
•	 The	most	accurate	diagnostic	approach:
i	Skin	test	standardization,	sensitivity,	specificity,	and	pre‐
dictive	values	for	most	drugs
ii	A	standardized	protocol	for	performing	drug	provocation	
test
iii	The	role	of	in	vitro	tests	for	diagnosis
•	 The	mechanism	of	 inhibition	 in	 rapid	drug	desensitization	
procedure
Future research questions and prospects for chronic 
rhinosinusitis
•	 Could	local	 IgE	measurement	be	used	for	the	diagnosis	of	
local	allergic	rhinitis?
•	 Could	nasal	cytology	be	used	in	the	study	of	chronic	rhinitis,	
especially	for	the	differential	diagnosis	of	chronic	rhinitis?
•	 Can	we	provide	the	diagnostic	standard	of	local	IgE	deter‐
mination	for	allergic	rhinitis	and	local	allergic	rhinitis?
•	 Can	we	provide	the	diagnostic	standard	of	nasal	eosinophil	
count	for	nonallergic	rhinitis	with	eosinophilia	syndrome?
     |  2303BREITENEDER ET al.
4  | UNMET NEEDS AND FUTURE 
RESE ARCH ARE A S IN TRE ATMENT OF 
ALLERGIC DISE A SES
4.1 | How to treat food allergy in the future: new 
developments and concepts
We	 are	 observing	 a	 pandemic	 increase	 in	 food	 allergy	 and	 ap‐
proaching	an	era	of	efficient	treatments.	In	peanut	allergy	oral	im‐
munotherapy	(OIT),	phase	III	studies	on	AR101152	in	peanut	allergic	
patients	 and	 phase	 II(b)	 and	 III	 studies	 on	 epicutaneous	 immuno‐
therapy	(EPIT)	for	milk	and	peanut153,154	have	been	conducted.	The	
FDA	application	for	AR101	is	submitted,	while	peanut	EPIT	submis‐
sion	has	been	retracted	to	provide	additional	technical	information.	
Different	ways	of	application	differ	with	regard	to	efficacy	of	desen‐
sitization;	however,	 all	 current	 applications	are	 linked	 to	an	avoid‐
ance	 regimen	 and	 it	 is	 unclear	 how	 long	 the	 individual	 treatment	
needs	 to	be	applied.	Consistent	data	 from	conventional	high‐dose	
milk,	peanut,	and	egg	OIT	report	good	efficacy	with	regard	to	desen‐
sitization.155,156	Therefore,	 in	addition	to	these	highly	standardized	
products,	OIT	using	conventional	food	sources	may	become	a	more	
frequent	treatment	offered	by	clinicians	in	the	community	as	a	result	
of	excessive	demand	in	the	absence	of	guidelines	and	recommenda‐
tions.	As	a	first	step,	the	European	Academy	of	Allergy	and	Clinical	
Immunology	(EAACI)	stated	to	consider	OIT	for	these	three	foods	in	
settings	with	the	appropriate	infrastructure	and	experience.155
The	major	issues	in	treating	food	allergy	by	immunotherapy	are	
safety,	the	low	rate	of	tolerance	induction,155	a	high	rate	of	side	ef‐
fects	and	dropouts,153	a	lack	of	understanding	of	the	optimal	dose	
and	 time	 of	 treatment,	 and	 the	 existence	 of	 only	 few,	 suboptimal	
biomarkers	 that	 predict	 treatment	 response	 and	 how	 to	 perform	
multifood	 OIT.13,157,158	 These	 limitations	 are	 addressed	 in	 numer‐
ous	 treatment	 approaches:	 (a)	 peptide	 immunotherapy	 targeting	
the	T‐cell	 compartment	 and	 lacking	 IgE	 cross‐linking159‐161;	 (b)	 hy‐
poallergenic	variants	of	allergens	or	extracts	by	chemical	or	thermal	
modification162,163	 or	 mutations	 which	 combine	 reduced	 desensi‐
tization	with	a	minimally	altered	T‐cell	 epitope	diversity164;	 (c)	 the	
usage	of	immunomodulatory	substances	and/or	particles165;	(d)	the	
addition	of	prebiotics	and/or	probiotics76,166;	 (e)	 the	application	of	
biologics	either	alone167,168	or	as	adjuvants	of	OIT169,170;	(g)	very	low	
dose	OIT171,172;	and	(h)	sublingual	OIT.
Recent	methodological	 developments	on	 cloning	 and	 antibody	
generation	 from	 single‐cell	 sorting	 of	 allergen‐specific	 B	 cells	will	
allow	 novel	 insights	 on	 the	 nature	 of	 peanut‐specific	 B‐cell	 re‐
sponses	and	may	give	rise	to	novel	high‐affinity	blocking	antibody	
treatments.173
4.2 | Treatment of allergic diseases with biologics
Molecular	mechanisms	of	type	2	inflammation	in	allergic	disease	are	
discussed	above.	Treatment	of	allergic	disease	with	biologicals	par‐
ticularly	targets	type	2	inflammation.	For	several	years,	omalizumab	
was	the	only	broadly	applied	biological	in	allergic	diseases	in	child‐
hood	and	adult	asthma174	and	chronic	urticaria.8,175	Recently,	phase	
III	 trials	demonstrated	efficacy	by	blocking	 the	 IL‐4/IL‐13	pathway	
in	 glucocorticoid‐dependent	 severe	 asthma,	 moderate‐to‐severe	
uncontrolled	 asthma,176,177	 CRSwNP,178	 and	 atopic	 dermatitis179 
(dupilumab),	 by	 blocking	 IL‐5	 in	 severe	 eosinophilic	 asthma	 (me‐
polizumab,180	reslizumab181)	and	CRSwNP	and	severe	uncontrolled	
asthma	by	blocking	 the	 IL‐5	 receptor	 (benralizumab182,183).184	FDA	
and	EMA	approved	mepolizumab,	reslizumab,	and	benralizumab	for	
adult	 uncontrolled	 asthma	 and	 dupilumab	 for	 atopic	 dermatitis	 in	
adolescents	and	adults,	and	these	biologics	are	integrated	in	current	
guidelines	and	position	papers.12,175,185,186	New	indications	for	these	
biologicals	can	be	expected	in	the	near	future.184,187
Novel	data	arising	from	a	long	pipeline	of	cytokine	and	chemok‐
ine	receptor	targeting	drugs	will	lead	to	additional	treatment	options	
and	change	the	 landscape	of	 therapeutics	 in	other	atopic	diseases	
including	food	allergy,	chronic	rhinosinusitis	with	nasal	polyps,12,188 
and	systemic	mastocytosis.189	Biologics	may	also	 increase	efficacy	
and	safety	of	AIT.
Phase	 II	 trials	 of	 biologics	 targeting	 type‐2	 pathways	 beyond	
IL‐4,	IL‐5,	and	IL‐13	are	encouraging.	Tezepelumab	blocking	the	TSLP	
receptor	 showed	 efficacy	 in	 uncontrolled	 asthma	 independent	 of	
eosinophil	counts.190	Nemolizumab	blocks	the	IL‐31R‐alpha	and	re‐
duces	pruritus	and	to	a	certain	extent	also	dermatitis	severity.191	It	
Unknowns in the treatment of food allergy
•	 Which	markers	predict	treatment	response?
•	 Which	 markers	 can	 be	 used	 to	 monitor	 tolerance	
development?
•	 What	is	the	optimal	dose	and	time	of	treatment?
•	 Is	there	a	role	for	biologics	to	improve	safety	and	efficacy	of	
immunotherapeutic	approaches?
•	 What	is	the	best	route	to	apply	immunotherapy?
•	 How	 can	 we	 implement	 oral	 immunotherapy	 safely	 in	 a	
community	setting?
•	 How	 to	 modify	 allergen	 formulations	 for	 tolerance	
induction?
Gaps in the treatment of allergic disease with 
biologics
•	 How	to	predict	treatment	response?
•	 Will	new	biologics	help	to	promote	tolerance	induction?
•	 How	to	define	precision	medicine	approaches	to	treat	se‐
vere	and	complex	atopic	phenotypes?
•	 Long‐term	side	effects	of	biologics?
•	 Safety	and	efficacy	of	biologics	in	childhood,	in	pregnancy,	
and	in	elderly?
•	 Novel	biomarkers	and	sets	of	biomarkers	will	be	needed.
•	 Treatment	algorithms	and	guidelines	for	biologics	usage	are	
needed.
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is	a	good	example	for	biologicals	with	the	potential	to	be	combined	
with	a	second	to	achieve	better	disease	control.	Another	important	
group	of	emerging	biologics	will	address	mucosal	inflammation44,192 
and	upstream	events	which	are	key	for	innate	lymphoid	cells	such	as	
anti–IL‐25	and	anti–IL‐33.
Costs	 are	 an	 important	 factor	 when	 prescribing	 biologics.	
Currently,	direct	treatment	expenses	only	partially	contribute	to	the	
overall	disease‐associated	financial	burden.193,194	Thus,	costs	related	
to	comorbidities195	and	the	impact	of	biologics	on	these	factors	will	
be	key.	The	development	of	biomarkers,	prediction	models,5,196	the	
design	of	 trials	comparing	different	biologics	and	the	 implementa‐
tion	of	strategies	to	investigate	the	safety,	function,	and	efficacy	in	
children,	the	elderly,	and	pregnant	women	represent	additional	cru‐
cial	challenges	that	need	to	be	answered	in	the	near	future.
4.3 | Small molecules for the treatment of 
allergic asthma
Several	targeted	therapeutic	options	for	asthma	and	related	con‐
ditions	 have	 been	 licensed	 in	 the	 past	 two	decades.	Apart	 from	
parenteral	monoclonal	antibodies	directed	against	key	inflamma‐
tory	 targets,	small	molecules	comprise	another	class	of	systemic	
medication	 interfering	 with	 inflammatory	 pathways	 underlying	
these	 disorders.197	 Leukotriene	 modifiers	 (LM),	 and	 specifically	
cysteinyl	 leukotriene	 (CysLT)	 receptor	 1	 antagonists	 (LTRA),	 are	
the	first	small	molecule	agents	widely	applied	for	targeted	treat‐
ment	of	asthma	and	comorbid	AR	both	in	adults	and	in	children.198 
Being	launched	in	an	evolving	era	and	lacking	adequate	biomark‐
ers,	initial	positioning	of	anti‐leukotrienes	in	asthma	treatment	has	
been	mainly	based	on	their	efficacy	in	clinical	models	and	not	on	
adequate	patient	stratification	which	may	have	delayed	proper	po‐
sitioning	of	this	targeted	therapy.199
More	 recently,	 another	 class	 of	 lipid	 mediator	 antagonists	
entered	 clinical	 development:	 antagonists	 of	 the	 prostaglandin	
D2	 (PGD2)	 receptor	 DP2	 also	 known	 as	 chemoattractant	 recep‐
tor‐homologous	 molecule	 expressed	 on	 Th2	 cells	 (CRTH2).200 
DP2/CRTH2	receptors	are	present	on	several	 inflammatory	cells	
including	mast	cells,	T‐helper	2	cells,	type	2	ILCs,	and	eosinophils,	
and	hence,	PGD2	plays	 an	 important	 role	 in	 linking	both	 the	 in‐
nate	 and	 adaptive	 immune	 system	 through	 type	2	 responses.201 
Although	 two	 compounds	 showed	 (modest)	 efficacy	 in	 allergen	
challenge,202,203	 many	 CRTH2	 antagonists	 failed	 in	 later	 clinical	
phases,	 possibly	 due	 to	 inadequate	 (non‐type	2)	 patient	 popula‐
tions.	With	the	emerging	evidence	of	an	upregulated	PGD2	path‐
way	and	its	association	with	type	2	inflammation	in	uncontrolled	
severe	eosinophilic	asthma,204	more	recently,	several	CRTH2	an‐
tagonists	have	been	tested	in	type	2	conditions,	including	allergic	
and/or	 refractory	 eosinophilic	 asthma,	 showing	 improvements	
in	several	clinical	outcomes.205‐209	In	a	post	hoc	analysis,	CRTH2	
antagonist	OC000459	 (Timapiprant)	 appeared	most	 effective	 in	
younger	(≤40	years)	patients	with	uncontrolled	atopic	eosinophilic	
asthma	 (blood	 eosinophils	 ≥	 250	 cells/μL).209	 Currently,	 several	
CRTH2	antagonist	programs	are	in	phase	III	studies	which	should	
help	 to	 consolidate	 phenotypes	 and	 biomarkers	 responding	 to	
these	 targeted	 drugs.	 Additionally,	 while	 the	 same	 immune/in‐
flammatory	cells	express	both	CysLT1	and	DP2/CRTH2	receptors,	
further	 research	 is	warranted	on	potential	 synergistic	 effects	of	
LTRA	and	CRTH2	antagonists	in	T2	inflammatory	conditions.
4.4 | Novel therapeutic concepts in AIT for 
airway disease
Allergen‐specific	 immunotherapy	 not	 only	 reduces	 symptoms	 in	
patients	with	AR,106	LAR,1	and	asthma,106,210	but	there	 is	also	evi‐
dence	 that	 AIT	 can	 reduce	 the	 development	 of	 asthma	 and	 new	
sensitizations,210‐212	thus	being	the	only	available	disease‐modifying	
treatment.	Altogether,	albeit	not	all	of	 the	highest	quality,	 there	 is	
evidence	that	AIT	can	halt	the	allergic	march	in	patients	with	AR.213 
Moreover,	 there	 is	 some	evidence	 that	AIT	 is	 cost‐effective	 in	AR	
with	or	without	asthma.214
Allergen‐specific	immunotherapy	is	usually	given	as	subcutane‐
ous	injections215,216	or	sublingually,217‐219	but	novel	treatment	forms	
such	 as	 peptide	 immunotherapy,11,220	 intralymphatic	 immunother‐
apy11,220	and	use	of	recombinant	allergens,	and	immune‐modulating	
adjuvants	and	nanoparticles21,220,221	are	under	development.
Despite	this	positive	profile,	AIT	is	only	used	for	highly	selected	
patient	groups	in	most	countries	in	Europe.109	The	reasons	for	this	
limited	 penetration	 are	multifold16,103,222	 but	 the	 long	 duration	 of	
the	 treatment,	 the	 potential	 side	 effects	 especially	 in	 groups	 that	
could	most	benefit	 from	AIT,	 and	 the	 inability	 to	predict	develop‐
ment	of	allergic	disease	and	response	to	AIT	treatment	are	among	
the	most	 important	ones.	Recently,	EAACI	has	been	very	active	in	
providing	guidelines	for	immunotherapy109,223	to	help	physicians	and	
patients	 in	 their	decisions.	However,	 for	 further	expansion	of	AIT,	
we	must	influence	the	balance	between	allergenicity	and	immuno‐
genicity,	which	can	improve	both	duration	of	treatment	and	create	
a	 better	 side	 effect	 profile.	 Furthermore,	we	 need	 greater	 under‐
standing	of	the	molecular	mechanisms	underlying	the	development	
Research needs for treatment with novel small 
molecules
•	 Sensitive	and	reliable	point‐of‐care	biomarkers	 to	 identify	
potential	 responders	 and	 to	 monitor	 (long‐term)	 effects	
of	 anti‐lipid	mediator	 small	molecules	 (LM,	 LTRA,	CRTH2	
antagonists).
•	 Combining	LTRA	and	CRTH2	antagonists	may	be	beneficial	
in	patients	with	type	2	inflammatory	conditions	and,	hence,	
warrants	further	clinical	investigation.
•	 Since	 both	 DP2/CRTH2	 receptors	 and	 CysLT1	 receptors	
are	present	on	both	 immune/inflammatory	and	structural	
cells,	apart	from	anti‐inflammatory	activity,	blocking	these	
receptors	may	potentially	 have	disease‐modifying	 effects	
(“anti‐remodeling”).
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of	respiratory	allergic	disease	and	of	AIT	at	the	level	of	the	individual	
patient,	facilitating	better	patient	stratification	for	AIT	to	further	im‐
prove	optimal	personalized	treatment.16,107
5  | CONCLUSIONS
Our	 specialty	has	been	evolving	at	 full	 speed	with	 the	 introduc‐
tion	 of	 several	 novel	 concepts	 such	 as	 knowledge	 of	 structures	
and	 biological	 functions	 of	 allergens	 to	 better	 understand	what	
makes	 them	allergenic,	molecular	mechanisms	of	 the	 type	2	 im‐
mune	response	and	 immune	tolerance.	Due	to	the	omics	revolu‐
tion	 and	 harnessing	 artificial	 intelligence	 to	 handle	 huge	 global	
datasets	to	facilitate	accurate	diagnoses	and	precise	and	personal‐
ized	monitoring	of	disease,	novel	treatments	are	highly	expected	
to	further	evolve.	Like	many	other	disciplines,	we	are	experiencing	
the	 early	 days	 of	 the	 development	 of	 new	 biologicals	 that	 have	
entered	 the	 clinic.	 Small	 molecules	 and	 combinations	may	 offer	
a	 rational	 alternative	 for	 the	 treatment	 of	 specific	 subtypes	 of	
asthma	 and	 related	 diseases.	 Future	 studies	 and	 head‐to‐head	
comparisons	 with	 the	 more	 expensive	 biologics	 should	 provide	
the	 answer.	 AIT	 is	 the	 only	 disease‐modifying	 treatment	 option	
for	allergic	patients.	Despite	 its	overall	favorable	profile,	the	use	
of	AIT	in	many	countries	is	still	limited.	For	further	dissemination	
of	AIT,	we	must	 influence	the	balance	between	allergenicity	and	
immunogenicity,	improve	the	vaccines	with	the	hope	for	long‐term	
cure	 in	many	 patients,	 and	 develop	 novel	 prevention	modalities	
for	early	 intervention,	which	can	overall	 improve	 the	efficacy	of	
treatment	and	create	a	better	side	effect	profile.	As	shown	in	the	
text	boxes	in	each	of	the	sections,	still	many	questions	are	waiting	
to	be	answered.
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